Home

Insights

PE

Alkem Laboratories Ltd P/E Ratio

Alkem Laboratories Ltd P/E Ratio

download
stocks purchased

₹ 1.3 Cr

Volume transacted

stocks purchased

2.4 K

stocks traded

Last Updated time: 16 Jul 15:30 PM

Image

Alkem Laboratories Ltd

NSE: ALKEM

PE

34

Last updated : 16 Jul 15:30 PM

Key Highlights

    The P/E Ratio of Alkem Laboratories Ltd is 34 as of 16 Jul 15:30 PM .a1#The P/E Ratio of Alkem Laboratories Ltd changed from 27.5 on March 2019 to 41.3 on March 2023 . This represents a CAGR of 8.47% over 5 years. a1#The Latest Trading Price of Alkem Laboratories Ltd is ₹ 5281 as of 16 Jul 15:40 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.5. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Alkem Laboratories Ltd changed from ₹ 20945 crore on March 2019 to ₹ 40626 crore on March 2023 . This represents a CAGR of 14.17% over 5 years. a1#The Revenue of Alkem Laboratories Ltd changed from ₹ 2627 crore to ₹ 3023 crore over 8 quarters. This represents a CAGR of 7.27% a1#The EBITDA of Alkem Laboratories Ltd changed from ₹ 254.65 crore to ₹ 477.63 crore over 8 quarters. This represents a CAGR of 36.95% a1#The Net Pr of Alkem Laboratories Ltd changed from ₹ 131.45 crore to ₹ 304.48 crore over 8 quarters. This represents a CAGR of 52.19% a1#The Dividend Payout of Alkem Laboratories Ltd changed from 23.91 % on March 2019 to 52.69 % on March 2023 . This represents a CAGR of 17.12% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Alkem Laboratories Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Alkem Laboratories Ltd

Period
Mar '1927.5
Mar '2024.7
Mar '2120.9
Mar '2226.3
Mar '2341.3

Company Fundamentals for Alkem Laboratories Ltd

Market Cap

64,362 Cr

EPS

158.2

P/E Ratio (TTM) *

34.0

P/B Ratio (TTM) *

6.2

Day’s High

5453.9

Day’s Low

5275.0

DTE *

0.1

ROE *

17.4

52 Week High

5581.2

52 Week Low

3440.05

ROCE *

17.7

* All values are consolidated

Last Updated time: 16 Jul 15:30 PM

* All values are consolidated

Last Updated time: 16 Jul 15:30 PM

Image

Alkem Laboratories Ltd

NSE: ALKEM

PRICE

5281.6

-101.45 (-1.88%)

stock direction

Last updated : 16 Jul 15:40

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Alkem Laboratories Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alkem Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Alkem Laboratories Ltd

Market Value

64,362

Asset Value

9,911

5.5 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Alkem Laboratories Ltd3464,362
Sun Pharmaceuticals Industries Ltd38380,451
Cipla Ltd28122,424
Divis Laboratories Ltd75121,461
Zydus Lifesciences Ltd31119,531
Dr Reddys Laboratories Ltd20113,324

Key Valuation Metric of Alkem Laboratories Ltd

Earnings

1,795 Cr

34.0 X

PE Ratio

Market Cap

₹64362Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

1,795 Cr

34.0 X

PE Ratio

Market Cap

₹64362Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Alkem Laboratories Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Alkem Laboratories Ltd

Period
Mar '1920945
Mar '2027845
Mar '2133146
Mar '2243248
Mar '2340626

* All values are a in crore

×

Historical Revenue of Alkem Laboratories Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Alkem Laboratories Ltd

Period
Jun '222628
Sep '223130
Dec '223086
Mar '232971
Jun '233034
Sep '233503
Dec '233418
Mar '243024

* All values are a in crore

×

Historical EBITDA of Alkem Laboratories Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Alkem Laboratories Ltd

Period
Jun '22255
Sep '22505
Dec '22644
Mar '23319
Jun '23455
Sep '23752
Dec '23750
Mar '24478

* All values are a in crore

×

Historical Net Profit of Alkem Laboratories Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Alkem Laboratories Ltd

Period
Jun '22131
Sep '22348
Dec '22460
Mar '2368
Jun '23288
Sep '23615
Dec '23604
Mar '24304

* All values are a in crore

×

Historical Dividend Payout of Alkem Laboratories Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Alkem Laboratories Ltd

Period
Mar '1924
Mar '2024
Mar '2121
Mar '2226
Mar '2353

* All values are a in %

About Alkem Laboratories Ltd

About Alkem Laboratories Ltd

    Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Ltd was incorporated as a private limited company on August 8, 1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988. In 1978, the company established its first plant at Taloja Maharashtra. In 1992, the company established its manufacturing facility in Mandwa, Maharashtra, which was later converted into an API facility in 2005. In 2003, the company set up a research and development facility for ANDA development at Taloja, Maharashtra. During the year 2006, the company's anti-infective drug Taxim became the first anti-infective drug in the Indian pharmaceutical industry to cross Rs 100 crore in terms of domestic sales in India. In 2007, the company filed its first ANDA in the US for the drug Amlodipine. In 2009, the company received first ANDA approval in US for Amlodipine. Also during the year, the company acquired Pharmacor Pty Ltd., a generic pharma company in Australia. In 2010, Alkem Laboratories acquired Ascend Laboratories, a generic marketing company in the US. In 2011, the company acquired Enzene, a company engaged in the development of biosimilars in India. In 2012, the company acquired an API manufacturing facility in the US. In 2014, the company acquired the 'Clindac-A' brand in India from Galderma S.A. Also during the year, Clavam crossed Rs 200 crore mark in terms of domestic sales in India. In 2015, the company acquired a formulation manufacturing facility in the US. During the FY2015,the company has done the stock split reduced the face value of equity share from Rs 10 to Rs 2 and also approved and allotted 59782500 bonus shares in the ratio of 1:1. On 23 December 2015, Alkem Laboratories successfully completed an Initial Public Offering (IPO) with its equity shares listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. On 10 May 2016, Alkem Laboratories announced that the Competition Appellate Tribunal (COMPAT) has passed an order dated 10 May2016 setting aside the penalty of Rs 74.63 crore imposed on the company by the Competition Commission of India (CCI) in its order dated 1 December 2015. On 7 June 2016, Alkem Laboratories announced the closure of the inspection by the United Kingdom - The Medicines and Healthcare Products Regulatory Agency (UK-MHRA) for its Bioequivalence facility at Taloja, Maharashtra, India. The facility stands UK-MHRA compliant. On 11 August 2016, Alkem Laboratories announced that the USFDA inspected the company's Bioequivalence facility at Taloja, Maharashtra, India from 1 August to 10 August 2016. At the end of the inspection, there were no 483s issued by the USFDA. On 28 October 2016, Alkem Laboratories announced that the USFDA conducted a Bio-analytical inspection at the company's manufacturing facility located at Daman, India from 24 October to 28 October 2016. The inspection has been cleared successfully without any 483 observations. This inspection was based on an ANDA filed by the company. On 7 February 2017, Alkem Laboratories announced that it has entered into an alliance with Haw Par India Pvt Ltd., a wholly owned subsidiary of Haw Par Healthcare Ltd., Singapore to exclusively market, sell and distribute Tiger Balm range of products in India. Tiger Balm products will be promoted by Alkem Healthcare, an Over the Counter (OTC) division of Alkem. Tiger Balm range of products is an internationally known remedy for headaches, upper respiratory congestions, rheumatic or arthritic pains and muscular sprains. Its unique blend of herbal ingredients, derived from an ancient Chinese source, has been proven effective for nearly 100 years and is trusted by millions of people in more than 100 countries. On 29 March 2017, Alkem Laboratories announced that the USFDA has issued an Establishment Inspection Report (EIR) for its Ankaleshwar API facility which was inspected in December 2016. The inspection has now been closed by the USFDA. The USFDA had inspected the Ankaleshwar API manufacturing facility from 5 to 9 December 2016 and had issued Form 483 with three observations. Post this, the company had submitted a detailed corrective and preventive action plan (CAPA) to the regulator within the stipulated timelines. The USFDA has reviewed the CAPA and has found them acceptable. On 10 January 2018, Alkem Laboratories announced the closure of USFDA inspection at its Baddi facility in Himachal Pradesh. On 28 March 2018, Alkem Laboratories informed the stock exchanges that the USFDA conducted an inspection at the company's manufacturing facility located at Amaliya, Daman, India from 19 March 2018 to 27 March 2018. Post the inspection, the company has received a Form 483 with thirteen observations. The company said it will put together a detailed response with adequate corrective and preventive measures to address the USFDA observations within the timeline stipulated by the USFDA. The USFDA also conducted an inspection at the company's manufacturing facility located at St. Louis, USA from 12 March 2018 to 16 March 2018. In response to the one Form 483 observation issued by the USFDA, the company has submitted a detailed corrective and preventive action plan (CAPA) plan to the regulator within the stipulated timelines. During the FY2019, the wholly owned subsidiary of the Company Alkem Laboratories (NIG) Limited was dissolved w.e.f. 06th May, 2018 pursuant to voluntary winding up. As on 31 March 2019,the company had 20 subsidiary companies under its roof. In FY 2018-19, the company invested Rs 4.62 billion or 6.3% of total revenues in R&D, compared to 5.7% in FY 2017-18. The company filed 23 ANDAs during the year and received 21 approvals, which includes 6 tentative approvals. The company have a fairly strong product pipeline of 127 ANDAs (as on 31st March, 2019) already filed with the USFDA, with over half of them yet to be commercialised. The Company has also made investments in the biosimilar segment through its subsidiary Enzene Biosciences - a biotech-focussed company located in Pune (Maharashtra, India). The company bagged Express Pharma Excellence Award at Pharma CXO Summit 2019. During the FY2020, a new company named Ascend Laboratories SAS was incorporated on 04th June, 2019 as a wholly owned subsidiary of the Company in Colombia. Also on 08th April, 2020, a new company named S&B Pharma LLC had been incorporated as a Step down subsidiary of the Company in USA. As on 31 March 2020,the company had 21 subsidiary companies under its roof. During the year 2019-20, the company invested Rs 4,726 million or 5.7% of total revenues in R&D, as against Rs 4,622 million in FY 2018-19. The company filed 18 ANDAs during the year and received 22 ANDA approvals which includes 6 tentative approvals. Alkem now has a total of 144 ANDAs (as on 31st March, 2020) filed with the USFDA and 89 approvals. During the quarter ended 30 June 2020, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 2 approvals (including 1 tentative approval). As on June 30, 2020, the Company filed a total of 146 ANDAs and 2 new drug applications (NDA) with the USFDA. Of these, it has received approvals for 88 ANDAs (including 13 tentative approvals) and 2 NDAs. During the quarter ended 30 September 2020, the Company filed 1 abbreviated new drug applications (ANDAs) with the US FDA and received 4 approvals (including 1 tentative approval). As on September 30, 2020, the Company has filed a total of 147 ANDAs and 2 new drug applications (NDA) with the USFDA of which it has received approvals for 91 ANDAs (including 13 tentative approvals) and 2 NOA. During the quarter ended 31 December 2020, the Company received 10 approvals (including 2 tentative approvals) from the USFDA. As on December 31, 2020, the Company has filed a total of 147 ANDAs and 2 new drug application (NDA) with the US FDA of which it has received approvals for 100 ANDAs (including 14 tentative approvals) and 2 NOA. In FY'20, Company started new formulation manufacturing facility in Indore and a new biologic / biosimilar manufacturing facility in Pune. S&B Pharma LLC has been incorporated as a step down subsidiary of the Company in USA on 08th April, 2020, and on 12th June, 2020, the Company acquired M/s Connect 2 Clinic Private Limited, a Company incorporated under the Companies Act, 2013. For business synergies, ease of administration and simplification in the organization structure for its business operations in USA market, the Company's Board of Directors at its meeting held on 25 May 2021 has approved the proposed plan for restructuring of the USA business operations by bringing both the subsidiary entities namely, S & B Pharma Inc, USA ('S & B') (engaged in manufacturing of pharmaceutical products and contract research) and The PharmaNetwork LLC, USA ('TPNC') (engaged in sales & marketing of pharmaceuticals products) under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands ('S & B BV'). This Board approved restructuring is subject to necessary statutory and regulatory approvals. During the quarter ended 31 March 2021, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 10 approvals (including 3 tentative approvals). During the FY2021,the Company filed 9 ANDAs with the US FDA and received 25 approvals (including 6 tentative approvals). As on March 31, 2021, the Company filed a total of 150 ANDAs and 2 new drug applications (NDA) with the US FDA. Of these, it has received approvals for 108 ANDAs (including 16 tentative approvals) and 2 NDAs. In FY'21, First product was launched from Enzene Biosciences in India. The Company ventured into respiratory segment in India with the launch of Pulmocare division. Connect2Clinic, the Company's online platform for participating medical professionals and healthcare staff to connect with their patients, witnessed a significant surge in activity. In FY'21-22, Connect2Clinic crossed an important milestone of 1 lakh doctor consultations and is growing fast to become a preferred end-to-end OPD management platform in India. During the year 2022-23, Enzene Inc., was incorporated as a step down subsidiary of the Company in USA on 26th May, 2022 and Pharmacor Limited, incorporated as a step down subsidiary of the Company in New Zealand on 01st June, 2022. The Company launched Adalimumab in the domestic markets in 2023. A new Marketing and Sales division, Metanext was launched in the Chronic segment.

Alkem Laboratories Ltd News Hub

News

Alkem incorporates WoS named Alixer Nexgen Therapeutics

Alkem Laboratories announced that a Wholly Owned Subsidiary (“WOS”) of the Company in the ...

Read more

15 Jul 202415:39

News

Alkem Laboratories Ltd up for fifth session

Alkem Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting a...

Read more

09 Jul 202413:01

News

Alkem Laboratories Ltd soars 1.34%, rises for third straight session

Alkem Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs...

Read more

05 Jul 202413:05

News

Alkem Laboratories to convene AGM

Alkem Laboratories announced that the 50th Annual General Meeting (AGM) of the company wil...

Read more

28 Jun 202419:25

News

USFDA concludes inspection of Alkem's Baddi unit

Alkem Laboratories announced that the US FDA has issued an Establishment Inspection Report...

Read more

25 Jun 202412:09

News

Alkem Labs gains as Baddi facility gets EIR from USFDA

The inspection has been classified as voluntary action indicated (VAI) and has been closed...

Read more

25 Jun 202411:59

Product Composition by Percentage (Revenue)

FAQs for PE of Alkem Laboratories Ltd

What is Alkem Laboratories Ltd current share price?

The current market price of Alkem Laboratories Ltd as of July 16, 2024 is ₹5281.60.

Is Alkem Laboratories Ltd a good investment?

As per BlinkX Score Alkem Laboratories Ltd scores 58 in Revenue, 45 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Alkem Laboratories Ltd's total net assets?

According to Alkem Laboratories Ltd's most recent financial filings, the company's net assets total ₹9910.8 Cr.

Is Alkem Laboratories Ltd making a profit or loss?

Alkem Laboratories Ltd's net Profit as of July 16, 2024 is close to ₹1,795 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199